FDA Disagrees With GAO’s “Unusual” Findings Regarding Plan B Decision
This article was originally published in The Tan Sheet
Reports from FDA officials vary as to the timing of the decision not to approve Barr's emergency contraceptive Plan B for over-the-counter sale, GAO's investigation into the application process reveals (see chart: "1Brief Timeline of Major Plan B Events Related to the Initial OTC Switch Application").
You may also be interested in...
Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
The State of Wisconsin has filed a citizen petition to persuade FDA to move Barr Labs' Plan B and any equivalent emergency contraceptives to OTC status without an age restriction